Introduction
The proliferation of antibiotic resistant bacteria has reached the point where close to 100,000 infections occur in the U.S. per year caused by methicillin-resistant Staphylococcus aureus (MRSA), leading to 18,650 deaths (in 2005; 44), a total greater than the 17,011 deaths the same year from HIV/AIDS according to the CDC (http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2005report/table7.htm). The spread of resistance (2, 21 ,51) has long stimulated efforts to find new antibiotics by a variety of methods, such as altering existing antibiotics, screening chemical (e.g. 18) or peptide (32, 43) libraries for specific inhibitors (e.g. 18), or targeting new proteins or processes (12, 32, 35, 47, 59 ). Recent efforts have also involved detecting new targets through genomics (66, 67) , such as bioinformatics screening for novel producers of peptide antimicrobials (8) , and finding new sources of antibiotics via metagenomics (e.g. 68) . Some authors have suggested that discovering new molecular scaffolds for antibiotics should be a priority (29) . Another approach involves potentiating existing antibiotics by identifying targets for increasing susceptibility to specific antimicrobials (see review; 19), such as the AmgRS-mediated stress response to the action of aminoglycosides in Pseudomonas aeruginosa (49), or bacterial nitric oxide synthases (33) . This has been achieved clinically in the case of inhibitors of -lactamase with -lactam antibiotics (see review by Buynak, 15).
A related example is the imipenem/cilastatin combination (36, 38) . Cilastatin is an inhibitor of DHP-1, a human renal dehydropeptidase-1 that hydrolyzes the -lactam imipenem (36) .
In the laboratory, inhibitors of efflux pumps have been used together with tetracycline in E.
coli (63) , and levofloxacin in Pseudomonas aeruginosa (56), but these have not been successfully used in a clinical setting. Tools are now available for more extensive systematic searches for targets for such potentiating codrugs. A transposon library has been used to detect genes responsible for increased sensitivity to one of a set of antibiotics in Acinetobacter bayli (31) , and comprehensive transposon mutant libraries of Psudomonas on June 27, 2017 by guest http://aac.asm.org/ Downloaded from aeruginosa (41, 54) have been used to screen for sensitivity to tobramycin (49) and ciprofloxacin (10), and a somewhat less defined transposon library has been used to detect sensitivity to one of a set of six antibiotics (28) . A comprehensive transposon library has also been constructed for Francisella novicida (30) . In yeast, a deletion library has been screened against a set of four DNA damaging agents (74) , and also a set of over 400 small molecules (37) . In the work reported here, we have expanded our previous work (73) and used high throughput screening of an Escheirchia coli knockout collection of close to 4,000 strains, each with a different gene inactivated (6) , to look for mutants that are more susceptible to one of 14 different antibiotics (see Table 1 ). We then used a reduced set of 283 identified strains to examine an additional 8 antibiotics, with the intent of finding a core set of tester strains. Many mutants are more susceptible to a wide range of antibiotics and represent the basic intrinsic resistance framework, but others are more specific, and allow us to define "barcodes" for the rapid typing of antibiotics with different target activities.
These results also help to define new combinational drug targets, as most of the mutants do not result in growth inhibition in the absence of subinhibitory or sublethal concentrations of an antibiotic. Moreover, combining mutations with increased sensitivities would allow the design ofmore precise tests for the persistence of antibiotics in foods, milk, and various wastewaters.
MATERIALS AND METHODS
E. coli strains. The Keio collection is as described in Baba et al. (6) in that LB medium was used, and that somewhat more cells were applied to each spot). All determinations were carried out on strain sets that were prepared from purified colonies.
The tests were repeated up to 6 times in some cases, and at varying concentrations (see Supplementary Data). The antibiotics used in the Tamae et al. study (73) were retested along with the new antibiotics, using additional concentrations, and the somewhat different conditions, to standardize scoring. The concentrations reported for compounds such as the aminoglycosides might be different in the LB medium used here than in other media, although we did not find reproducible differences when the NaCl was left out of the LB medium in the two cases tested (tobramycin and gentamicin). Cross resistance between some of the aminoglycosides, particularly neomycin, and the kanamycin resistance marker in the strains used might alter the concentrations that are effective, but we found this to be the case only for neomycin. We found prominent patterns for neomycin at the concentrations reported.
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Validation of the data set. A collection of 4,000 strains will contain some errors, and some impure strains. The latter problem can be minimized by repurifying and retesting, as was done here. Also, in a number of cases, strains pick up suppressors that will attenuate the effects of the deletion knockouts. We have re-isolated several strains to eliminate this effect. Thus, the copies of strains with oxyR and recA are somewhat different than those reported previously (73) . Mori and coworkers have subjected the KEIO collection to an intensive analysis aimed at uncovering errors in the collection that might arise from duplications of the target gene. They have generated a list of 14 mutants that are incorrect, and another 9 that might be incorrect. We have therefore removed coaE, glmM, parC, prfB, polA, rpoD, rpsU from our data sets. Ultimately, the most prudent use of such a large collection is to verify any mutants that are particularly important to the final results by PCR analysis, and/or sequencing. We examined in detail some of the more important assignments. We took an expanded set of 12 of the mutants from the bar-code that are used to identify specific antibiotics (see Table 4 ), (recF, argO, degP, dacA, glpD, trxB, xseA, sapC, rplI, tufA, ycdZ, dinB,) as well as recA, oxyR, flgB, ppiD, and rpsF and using two primer pairs for each verified in two PCR experiments for each that each carried a kan insert in place of the correct gene, and that there was no presence of the original gene sequence elsewhere (via a duplication). In the case of rpsF, we carried out both PCR and sequencing. Moreover, an additional two from Table 4 can be identified by their phenotypes (dam, mutator; lon, muccoid formation). This constitutes a verification of 19 mutants, most of which are key indicators for specific antibiotics. We had reason to suspect the recF deletion mutant, and a similar analysis revealed that the recF deletion strain in the first copy of the KEIO strains is incorrect, although the recF strain in the second is correct, and this has been used in the work reported here. Regarding further validation, we have detected all four of the genes found through biochemical experiments that when mutated render the cell more sensitive to CPR (25), and all six of the genes for NIT (64) .
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RESULTS AND DISCUSSION
Screening for antibiotic hypersensitivity. The entire Keio collection of close to 4,000 strains (6) was screened for mutants that are more sensitive than the wild-type to one or more of a set of 14 different antibiotics (see Table 1 ). We first examined CIP, VAN 
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Yet, mutants lacking the thioredoxin/thioredoxin reductase system (trxA, trxB) are specifically sensitive to RIF.
Antibiotic identification:
We can designate a minimal set of 13-15 strains that when compared allow identification of almost all of the antibiotics used here, as depicted in Table   2 . In some cases further testing with other mutants from Figure 4 can distinguish between members of general groups (fluroquinolones, aminoglycosides, -lactams antibiotics, and mildly increased sensitivity to some of the four aminoglycosides tested, is exhibited by mutants lacking the ability to respond to DNA damage or damaging agents (e.g. dinG, xseB, gshB). We can use the specific sensitivity profiles defined here to type new antibiotics, with significantly less effort than for microarray studies, particularly if we employ the reduced set of strains shown in Figure 4 , or in Table 2 . In principle, these data complement the data from microarrays (13,40,42,69), since each method has a different, although not totally independent basis for scoring. Microarrays measure the change in gene expression in response to a subinhibitory concentration of an antibiotic, whereas the profiles such as those in Figures 1-4 measure specific phenotypes. Moreover, some of the strains shown in Figure 4 can be used in the initial screening for specific antibiotics. Previous workers have used engineered strains to aid in the detection of antibiotics from soil isolates (24,39).
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As noted above, the data in this work further defines the intrinsic resistome, as has work in other microorganisms (e.g. 10,28,31,37); as we dismantle the cell s intrinsic protection the cell becomes more sensitive. We have shown that certain double mutants are even more sensitive than their parents alone (73) . We can apply the knowledge of the property of double and triple mutants to construct improved strains useful for detecting the presence of antibiotics in the environment, such as in milk or hospital waste water, as is done with the Delvotest SP-NT and the Copan Milk Test (48), and have already developed some preliminary tests. 
